Zonagen Updates Vasomax Mechanistic Brown Fat in Rats Study
Joseph S. Podolski, President and CEO of Zonagen, said, "We are satisfied with the interim results of the mechanistic study. However, it is important to exercise caution in interpreting the effect this interim outcome will have on the overall assessment by the FDA. Once the study is finalized, we will work with our consultants to present a scientifically accurate interpretation of the overall results. At that time, we can fully appreciate the impact that the data will have on the clinical hold on Vasomax(R) in the U.S."
Zonagen, Inc. is engaged in the development of pharmaceutical products for the reproductive system, including sexual dysfunction, vaccine adjuvants, products for fertility and female health as well as urological applications, specifically prostate cancer.
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.